We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Explains changes to drug driving law and the guidance available for healthcare professionals and users of prescription medicine.
Guidance on how to license electronic cigarettes and other inhaled nicotine-containing products (NCPs) as medicines in the UK.
Webinars for pharmaceutical companies, clinical trial sponsors, e-cigarette producers and brokers of medicinal products
A wholesale dealer in Great Britain may import Qualified Person certified medicines from the European Economic Area if certain checks are made by the ‘Responsible Person (import)’
Information for wholesale dealer licence holders about the medicines put on the UK market for UK patients that they cannot export or hoard.
How to account for VAT on goods and services provided by registered health professionals, including doctors, dentists, nurses and pharmacists.
Safety leaflet on opioid medicines to help patients and their families reduce the risks of harm.
Examines factors influencing the 5.19% growth in branded medicines under the Pharmaceutical Price Regulation Scheme (PPRS) in 2013 to 2014.
Who in the pharmaceutical industry can be a Marketing Authorisation Holder, named distributor or local representative and how to make changes to these.
Information for patients, healthcare professionals and developers of new medicines
Monthly PDF editions of the Drug Safety Update newsletter from MHRA and its independent advisor, the Commission on Human Medicines
Guidance for UK wholesalers and manufacturers on how to import human medicines including unlicensed medicines, how to apply for a licence and how much it costs.
Sets out the payment due from members of the voluntary scheme for branded medicines pricing and access in 2023.
Falsified, potentially harmful Ozempic▼ and Saxenda products have been found in the UK.
How to show MHRA you're meeting good clinical practice (GCP) standards and what to expect from an inspection.
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals...
Intellectual property research publications commissioned by the Intellectual Property Office (IPO) covering trade marks and brands.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab).